Dec 6 Supernus Pharmaceuticals Inc's
treatment for attention deficit hyperactivity disorder met the
main goal of two trials, but shares fell about 16 percent on
Thursday as the data failed to convince some investors that the
drug was better than rivals.
A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.
A non-opioid drug developed by Pfizer and Eli Lilly met the main goals of a late-stage study, in which over half of the patients reported a significant reduction in osteoarthritis pain of the knee or hip.
Alnylam Pharmaceuticals Inc said on Thursday it might have to hold off on plans to seek an accelerated approval for its gene-silencing drug, which showed effectiveness in a late-stage trial based on early data.